证券代码：300676 证券简称：华大基因 公告编号：2025-063 深圳华大基因股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《深圳华大基因股份有限公司章程》（以 下简称《公司章程》）的有关规定，经深圳华大基因股份有限公司（以下简称公 司）第四届董事会第七次会议审议通过，公司董事会决定于2025年11月12日（星 期三）召开公司2025年第二次临时股东会。《关于召开2025年第二次临时股东会 的 通 知 》（ 公 告 编 号 ： 2025-061 ） 已 于 2025 年 10 月 24 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn，下同）进行了公告。本次会议将采取现场表决与网 络投票相结合的方式召开，根据相关规定，现就本次会议有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025年第二次临时股东会 7、会议出席对象： （1）截至2025年11月6日（星期四）下午收市时，在中国证券登记结算有限 责任公司深圳分公司 ...

Core Viewpoint - The meeting between the Prime Minister of Serbia and the CEO of BGI Group highlights the importance of collaboration in life sciences, agriculture, and education, with a focus on improving the quality of life for the Serbian population [1] Group 1 - The Serbian Prime Minister, Marcut, praised BGI Group's technological strength and its operations in Serbia [1] - Serbia is committed to advancing research and industrial development in the life sciences sector [1] - BGI Group expresses a strong willingness to contribute to major development projects in healthcare, education, and technology in Serbia [1]

Group 1 - On November 3, BGI Genomics conducted a block trade of 100,000 shares, with a total transaction value of 4.427 million yuan, accounting for 1.37% of the total trading volume for the day [1] - The transaction price was 44.27 yuan per share, which represents a 10% discount compared to the market closing price of 49.19 yuan [1] - The buyer of the block trade was an institutional investor, while the seller was Huafu Securities Co., Ltd. South China Branch [2]

Group 1 - The forum on financial empowerment of the private economy attracted significant attention, reflecting the rising interest in private enterprises following high-profile discussions and the introduction of the Private Economy Promotion Law [1][4] - Experts discussed the challenges faced by private enterprises, particularly the issue of "involution" driven by price wars, and emphasized the need for innovation as a solution [4][5] - The importance of creating a conducive policy environment for innovation was highlighted, with a focus on finding a "golden balance" in competition to stimulate innovation and prevent monopolistic practices [5][6] Group 2 - Financial support is crucial for the growth of private enterprises, with data showing that nearly two-thirds of A-share listed companies are private, and private enterprise loan growth has outpaced average loan growth by 1.1 percentage points over the past five years [7][8] - The role of venture capital and early-stage investments in helping private enterprises navigate challenges and foster innovation was emphasized, with suggestions for policies to encourage early and small investments in hard technology [8][9] - Recommendations were made for establishing a technology finance support system led by enterprises, including the use of long-term special government bonds to create patient capital for strategic emerging industries [8][9]

Core Insights - The article highlights the recognition of Xu Qian, the Vice President and General Counsel of BGI Genomics, as one of the "Top 15 General Counsels in China" by Asian Legal Business, reflecting her outstanding contributions in legal exploration, technological innovation, and global compliance [1][4]. Group 1: Recognition and Awards - The "Top 15 General Counsels in China" list has been published for ten consecutive years, aiming to identify outstanding general counsels who demonstrate foresight, leadership, and significant influence in complex environments [4]. - Xu Qian's inclusion in the list is a testament to her exceptional legal skills and strategic understanding of business, which have redefined the role of general counsel and expanded its value boundaries [4]. Group 2: AI and Legal Compliance - BGI Genomics is integrating AI technology into its research platforms, data analysis, and clinical applications, enhancing diagnostic efficiency while ensuring data sovereignty and compliance [5]. - The company has launched innovative products, such as the "Hereditary Tumor Variation Knowledge Base," addressing gaps in domestic tumor precision diagnosis data products, supported by a robust legal compliance team [5]. Group 3: Globalization and Compliance Strategy - BGI Genomics is advancing its globalization strategy by establishing precision medicine laboratories and joint ventures in key overseas markets, promoting Chinese technology and standards internationally [6]. - Under Xu Qian's leadership, the company has developed an international compliance system, becoming the first in China to obtain ISO37301 compliance management certification, which enhances its global strategy and sets a positive example for industry compliance standards [6]. Group 4: Role Evolution of Legal Team - Xu Qian has transformed the legal team's role from risk managers to drivers of technological innovation and global strategy, emphasizing the critical value of legal expertise in the high-quality development of the life sciences sector [7]. - The legal team is expected to continue its focus on cutting-edge legal issues, providing strong legal support for corporate innovation and industry compliance upgrades [7].

Core Insights - The company reported that as of the end of Q3 this year, the total sample volume for its colorectal cancer screening project exceeded 400,000, generating nearly 100 million yuan in revenue [1] Group 1: Business Performance - The colorectal cancer screening project has shown significant growth with over 400,000 samples processed [1] - Revenue from this project is approaching 100 million yuan, indicating strong market demand [1] Group 2: Strategic Direction - The company plans to accelerate its transformation from a "testing service" model to a comprehensive model that includes "products + services + data" [1] - This strategic shift aims to establish a dual-driven model targeting both consumer (C-end) and business (B-end) markets [1]

Group 1: Business Development and Financial Performance - In Q3 2025, the company launched multiple public health projects across various regions, with over 400,000 colorectal cancer screening samples collected, generating nearly 100 million CNY in revenue [2][4] - The company's revenue decline narrowed to 5.39% in the first three quarters of 2025, indicating a positive trend, with infection control revenue increasing by 41.7% [14][15] - The precision medicine solutions segment saw a revenue increase of 11.2% due to a shift from ICL to IVD business models [14][17] Group 2: Product and Service Innovations - The company is transitioning from "detection services" to a comprehensive model of "products + services + data," focusing on both C-end and B-end markets [3] - New cancer screening services were launched, including non-invasive gastric cancer gene testing and cervical cancer DNA methylation testing [4] - The BISCUIT-seq technology was introduced for ctDNA detection, enhancing monitoring capabilities without relying on tumor tissue samples [5] Group 3: Market Strategy and Expansion - The company aims to expand its international presence, particularly in regions along the Belt and Road Initiative, with a focus on NIPT and WGS products [16][19] - Collaborations with hospitals and wearable device manufacturers are being strengthened to enhance health management solutions [13][19] - The company is actively responding to the NGS centralized procurement policy, aiming to optimize pricing structures while maintaining service quality [6][15] Group 4: Future Outlook and Challenges - The company is preparing for challenges posed by declining birth rates and macroeconomic fluctuations by focusing on core business areas and expanding product lines related to aging populations [18] - The introduction of the GeneT model aims to enhance diagnostic accuracy and operational efficiency in genetic testing [9][10] - The company anticipates steady improvement in gross margins for precision medicine as market penetration strategies evolve [17]

Financial Performance - BGI Genomics reported a revenue of 2.674 billion yuan for the first three quarters of 2025, a decrease of 5.39% compared to the same period last year [1] - The net loss for the same period was 21.39 million yuan, with a non-recurring net loss of 66.76 million yuan [1] - In Q3 2025, the revenue was 1.042 billion yuan, showing a year-on-year increase of 9.19%, while the net loss was 27.17 million yuan, with a non-recurring net loss of 36.28 million yuan [1] Shareholding Structure - As of September 30, 2025, Shenzhen BGI Technology Co., Ltd. held 29.77% of the shares, while Shenzhen Qianhai BGI Investment Enterprise (Limited Partnership) held 7.12% [2][4] - The top shareholders include BGI Technology Co. (29.77%), Shenzhen Shenghua Investment Enterprise (7.12%), and various funds with smaller stakes [3][4] Shareholder Transactions - Wang Jian, the founder, cashed out over 700 million yuan through the sale of 16.73 million shares at a price of 44.10 yuan per share, totaling 738 million yuan [9][10] - The shareholding of BGI Technology Co. decreased from 33.77% to 29.77% after the sale [7][8] - The overall shareholding of Wang Jian and his associates dropped from 38.17% to 31.32% following the transaction [7][8] Market Capitalization - As of the latest closing date, BGI Genomics' stock price was 47.82 yuan, giving the company a market capitalization of 20 billion yuan [14]

Core Insights - BGI Genomics (300676) reported a total revenue of 1,042,166,389.29 yuan for Q3 2025, marking a year-on-year increase of 9.19% [1] - The company experienced a net loss attributable to shareholders of 27,165,209.53 yuan in Q3 2025, which is an increase of 80.92% compared to the previous year [1] - For the first three quarters of 2025, total revenue was 2,673,638,742.11 yuan, reflecting a year-on-year decline of 5.39% [1] - The net loss attributable to shareholders for the first three quarters was 21,386,988.41 yuan, an increase of 82.78% year-on-year [1] Revenue Breakdown by Business Segment - The reproductive health segment generated revenue of 643 million yuan, down 28.4% year-on-year [2] - The oncology and chronic disease prevention segment reported revenue of 358 million yuan, a decrease of 8.8% year-on-year [2] - The infection prevention segment achieved revenue of 75 million yuan, showing a growth of 41.7% year-on-year [2] - The multi-omics and synthesis segment maintained revenue of 452 million yuan, remaining stable compared to the previous year [2] - The precision medicine testing comprehensive solution segment recorded revenue of 1,124 million yuan, an increase of 11.2% year-on-year [2] Shareholder Information - As of the announcement date, the controlling shareholder BGI Holdings and its concerted parties had pledged 79.18% of their total shareholding [2] - Shareholder Shenghua Investment has reduced its stake by 1,250,700 shares, accounting for 0.2990% of the company's total share capital, with the reduction plan still ongoing [2]

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. (BGI) demonstrated strong operational resilience and strategic determination in a complex industry environment, with significant improvements in profitability and operational quality despite short-term performance fluctuations [1][2]. Financial Performance - In the first three quarters of 2025, BGI achieved operating revenue of 2.674 billion yuan, with a notable reduction in net profit loss year-on-year. In Q3 alone, the revenue reached 1.042 billion yuan, reflecting a year-on-year growth of 9.19% [1]. Business Growth Areas - BGI's various business segments showed robust growth, particularly in cancer and chronic disease prevention, with colorectal cancer detection revenue increasing by approximately 9%. The infection prevention business saw a revenue increase of about 200% for the PTseq product series, while single-cell sequencing revenue grew by approximately 93%. The comprehensive solutions for precision medicine testing also experienced an 11.2% year-on-year growth [2]. Strategic Focus on Elderly Health - The company is strategically focusing on the health market centered around the elderly population, addressing chronic diseases such as genetic metabolic disorders, cardiovascular diseases, and cognitive impairments. BGI has launched multiple risk assessment products for cognitive disorders and cardiovascular diseases [2]. AI and Data-Driven Innovations - BGI is leveraging big data and artificial intelligence to transition the healthcare industry from expert-driven to data and intelligence-driven models. The company launched the GeneT multimodal model, which is now utilized by 241 partner institutions, enhancing genetic testing capabilities [3]. Health Management Solutions - BGI introduced the 133111i multi-omics health management model, which creates personalized health risk profiles and customizes intervention plans across the health management spectrum. The i99 Smart Health platform further advances health management into a new era of intelligence and personalization [3]. Gene Data Product Development - The company has made strides in gene data value transformation by launching the first domestic gene data products, including the "Hereditary Tumor Variation Knowledge Base" and "Tumor Somatic Variation and Medication Knowledge Base," filling a gap in the domestic market for precision oncology data products [3].